Feasibility and Safety of Intravenous Sotalol to Initiate Oral Sotalol Therapy in Atrial Fibrillation (DASH-AF)

Feasibility and Safety of Intravenous Sotalol to Initiate Oral Sotalol Therapy in Atrial Fibrillation (DASH-AF) - JCEP April 2023

Description

The DASH-AF trial shows that rapid IV sotalol loading in atrial fibrillation/flutter patients for rhythm control is feasible and safe compared with conventional oral loading with significant cost reduction. (Feasibility and Safety of Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients With Atrial Fibrillation [DASH-AF]).

Editor-in-Chief

Kalyanam Shivkumar, MD, PhD, FACC

CME Editor
Kenneth A. Ellenbogen, MD, FACC

Author
Kelvin Bush, MD, FACC

Important Dates
Date of Release: April 24, 2023
Term of Approval/Date of CME/MOC Expiration: April 23, 2024

Summary


Availability:	Retired


Cost:	FREE


Credit Offered:	No Credit Offered